Effect of Long-term, High-dose N-acetylcysteine on Exacerbations of Bronchiectaisis
Status:
Completed
Trial end date:
2018-03-30
Target enrollment:
Participant gender:
Summary
Objective: To evaluate whether long-term oral N-acetylcysteine as an expectorant drug can
reduce the frequency of acute exacerbations of patients with non-cystic fibrosis
bronchiectasis and improve their quality of life.
Methods: Patients with non-cystic fibrosis bronchiectasis will be randomly assigned to the
observer group (participants receive 600 mg of oral N-acetylcysteine BID for 12 months) or
the control group (participants receive oral tablet BID for 12 months). The primary endpoint
was the frequency of acute exacerbations.
Expected results: Compared with the control group, the frequency of acute exacerbations of
the observer Group will decrease significantly.
Hypothesis: Long-term oral N-acetylcysteine can reduce the frequency of acute exacerbations
of patients with non-cystic fibrosis bronchiectasis and improve their quality of life.
Phase:
N/A
Details
Lead Sponsor:
Qilu Hospital Qilu Hospital of Shandong University